Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Marker Therapeutics Inc’s stock clocked out at $1.7, down -11.46% from its previous closing price of $1.92. In other words, the price has decreased by -$11.46 from its previous closing price. On the day, 1.76 million shares were traded. MRKR stock price reached its highest trading level at $1.8899 during the session, while it also had its lowest trading level at $1.63.
Ratios:
To gain a deeper understanding of MRKR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.79 and its Current Ratio is at 6.79. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on March 05, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On March 25, 2021, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $6.
On March 19, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $6.Cantor Fitzgerald initiated its Overweight rating on March 19, 2021, with a $6 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 23 ’24 when ELMS STEVE bought 11,085 shares for $3.20 per share. The transaction valued at 35,472 led to the insider holds 325,370 shares of the business.
New Enterprise Associates 16, bought 554,250 shares of MRKR for $1,773,600 on Dec 23 ’24. The 10% Owner now owns 1,625,678 shares after completing the transaction at $3.20 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRKR now has a Market Capitalization of 19235160 and an Enterprise Value of 3618489. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.38 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 0.635.
Stock Price History:
The Beta on a monthly basis for MRKR is 1.47, which has changed by -0.65794766 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, MRKR has reached a high of $5.99, while it has fallen to a 52-week low of $0.95. The 50-Day Moving Average of the stock is 17.35%, while the 200-Day Moving Average is calculated to be -22.81%.
Shares Statistics:
It appears that MRKR traded 1.15M shares on average per day over the past three months and 6580970 shares per day over the past ten days. A total of 11.21M shares are outstanding, with a floating share count of 7.90M. Insiders hold about 30.21% of the company’s shares, while institutions hold 17.29% stake in the company. Shares short for MRKR as of 1749772800 were 173261 with a Short Ratio of 0.11, compared to 1747267200 on 127043. Therefore, it implies a Short% of Shares Outstanding of 173261 and a Short% of Float of 11.41.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 1.0 different market analysts. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.26 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$1.19 and -$1.19 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$0.68, with 1.0 analysts recommending between -$0.68 and -$0.68.
Revenue Estimates
A total of 2 analysts have provided revenue estimates for MRKR’s current fiscal year. The highest revenue estimate was $4.69M, while the lowest revenue estimate was $300k, resulting in an average revenue estimate of $2.49M. In the same quarter a year ago, actual revenue was $6.59M
